BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 21317458)

  • 1. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival.
    Powe DG; Voss MJ; Zänker KS; Habashy HO; Green AR; Ellis IO; Entschladen F
    Oncotarget; 2010 Nov; 1(7):628-638. PubMed ID: 21317458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is Beta-Blocker Use Beneficial in Breast Cancer? A Meta-Analysis.
    Kim HY; Jung YJ; Lee SH; Jung HJ; Pak K
    Oncology; 2017; 92(5):264-268. PubMed ID: 28132057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beta-adrenergic signaling, a novel target for cancer therapy?
    Schuller HM
    Oncotarget; 2010 Nov; 1(7):466-469. PubMed ID: 21317444
    [No Abstract]   [Full Text] [Related]  

  • 4. Expanding our therapeutic options: Beta blockers for breast cancer?
    Ganz PA; Cole SW
    J Clin Oncol; 2011 Jul; 29(19):2612-6. PubMed ID: 21632500
    [No Abstract]   [Full Text] [Related]  

  • 5. β-Blocker Use and Risk of Recurrence in Patients with Early Breast Cancer.
    Sakellakis M; Kostaki A; Starakis I; Koutras A
    Chemotherapy; 2014; 60(5-6):288-9. PubMed ID: 25998892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of beta-blockers and survival among hypertensive patients with renal cell carcinoma.
    Parker WP; Lohse CM; Zaid HB; Cheville JC; Boorjian SA; Leibovich BC; Thompson RH
    Urol Oncol; 2017 Jan; 35(1):36.e1-36.e6. PubMed ID: 27687543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta blockers and breast cancer mortality: a population- based study.
    Barron TI; Connolly RM; Sharp L; Bennett K; Visvanathan K
    J Clin Oncol; 2011 Jul; 29(19):2635-44. PubMed ID: 21632503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer.
    Melhem-Bertrandt A; Chavez-Macgregor M; Lei X; Brown EN; Lee RT; Meric-Bernstam F; Sood AK; Conzen SD; Hortobagyi GN; Gonzalez-Angulo AM
    J Clin Oncol; 2011 Jul; 29(19):2645-52. PubMed ID: 21632501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of beta blockers on epithelial ovarian cancer survival.
    Diaz ES; Karlan BY; Li AJ
    Gynecol Oncol; 2012 Nov; 127(2):375-8. PubMed ID: 22819786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy.
    Wang HM; Liao ZX; Komaki R; Welsh JW; O'Reilly MS; Chang JY; Zhuang Y; Levy LB; Lu C; Gomez DR
    Ann Oncol; 2013 May; 24(5):1312-9. PubMed ID: 23300016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metastasis Risk Reduction Related with Beta-Blocker Treatment in Mexican Women with Breast Cancer.
    Parada-Huerta E; Alvarez-Dominguez T; Uribe-Escamilla R; Rodriguez-Joya J; Ponce-Medrano JD; Padron-Lucio S; Alfaro-Rodriguez A; Bandala C
    Asian Pac J Cancer Prev; 2016; 17(6):2953-7. PubMed ID: 27356717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of β2-adrenergic receptor reduces triple-negative breast cancer brain metastases: The potential benefit of perioperative β-blockade.
    Choy C; Raytis JL; Smith DD; Duenas M; Neman J; Jandial R; Lew MW
    Oncol Rep; 2016 Jun; 35(6):3135-42. PubMed ID: 27035124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of non-selective β-blockers is associated with decreased tumor proliferative indices in early stage breast cancer.
    Montoya A; Amaya CN; Belmont A; Diab N; Trevino R; Villanueva G; Rains S; Sanchez LA; Badri N; Otoukesh S; Khammanivong A; Liss D; Baca ST; Aguilera RJ; Dickerson EB; Torabi A; Dwivedi AK; Abbas A; Chambers K; Bryan BA; Nahleh Z
    Oncotarget; 2017 Jan; 8(4):6446-6460. PubMed ID: 28031536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts.
    Cardwell CR; Pottegård A; Vaes E; Garmo H; Murray LJ; Brown C; Vissers PA; O'Rorke M; Visvanathan K; Cronin-Fenton D; De Schutter H; Lambe M; Powe DG; van Herk-Sukel MP; Gavin A; Friis S; Sharp L; Bennett K
    Breast Cancer Res; 2016 Dec; 18(1):119. PubMed ID: 27906047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. β-Adrenergic Receptors : New Target in Breast Cancer.
    Wang T; Li Y; Lu HL; Meng QW; Cai L; Chen XS
    Asian Pac J Cancer Prev; 2015; 16(18):8031-9. PubMed ID: 26745035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postdiagnostic use of β-blockers and other antihypertensive drugs and the risk of recurrence and mortality in head and neck cancer patients: an observational study of 10,414 person-years of follow-up.
    Kim SA; Moon H; Roh JL; Kim SB; Choi SH; Nam SY; Kim SY
    Clin Transl Oncol; 2017 Jul; 19(7):826-833. PubMed ID: 28093700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
    Regan MM; Neven P; Giobbie-Hurder A; Goldhirsch A; Ejlertsen B; Mauriac L; Forbes JF; Smith I; Láng I; Wardley A; Rabaglio M; Price KN; Gelber RD; Coates AS; Thürlimann B; ;
    Lancet Oncol; 2011 Nov; 12(12):1101-8. PubMed ID: 22018631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG.
    Heitz F; du Bois A; Harter P; Lubbe D; Kurzeder C; Vergote I; Plante M; Pfisterer J; ; ;
    Gynecol Oncol; 2013 Jun; 129(3):463-6. PubMed ID: 23500609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of the AJCC 8th edition staging system for selecting patients with T1-2N1 breast cancer for post-mastectomy radiotherapy: a joint analysis of 1986 patients from two institutions.
    Wang S; Wen G; Tang Y; Yang Y; Jing H; Wang J; Zhang J; Zhao X; Sun G; Jin J; Song Y; Liu Y; Fang H; Zhang Y; Li Y
    BMC Cancer; 2020 Aug; 20(1):792. PubMed ID: 32838753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer.
    Bayraktar S; Hernadez-Aya LF; Lei X; Meric-Bernstam F; Litton JK; Hsu L; Hortobagyi GN; Gonzalez-Angulo AM
    Cancer; 2012 Mar; 118(5):1202-11. PubMed ID: 21800293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.